SUVENPHAR.BOSUVENPHAR.BOBSE
Loading
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P36
Within normal range
Average
15.93%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | -100.00% |
| Q1 2024 | 287.53% |
| Q4 2023 | -48.99% |
| Q3 2023 | 114.27% |
| Q2 2023 | -68.25% |
| Q1 2023 | 189.75% |
| Q4 2022 | 9.41% |
| Q3 2022 | -7.06% |
| Q2 2022 | 4.11% |
| Q1 2022 | -2.02% |
| Q4 2021 | -40.36% |
| Q3 2021 | 55.99% |
| Q2 2021 | 56.17% |
| Q1 2021 | -43.34% |
| Q4 2020 | -30.30% |
| Q3 2020 | 23.90% |
| Q2 2020 | -9.67% |
| Q1 2020 | 26.62% |
| Q4 2019 | -49.16% |
| Q3 2019 | 93.38% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |